Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5701 to 5715 of 7682 results

  1. For isoniazid-resistant TB, what is the most effective regimen for reducing mortality andmorbidity?

    Recommendation ID NG33/3 Question For isoniazid-resistant TB, what is the most effective regimen for reducing mortality andmorbidity?

    Research recommendation
    Published
    8 November 2019

  2. Treating small oesophageal varices:- Do non-selective beta-blockers improve survival and prevent first variceal bleeds in people with cirrhosis that is associated with small oesophageal varices?

    Recommendation ID NG50/2 Question Treating small oesophageal varices:- Do non-selective beta-blockers improve survival and prevent first

    Research recommendation
    Published
    25 August 2016

  3. What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?

    Recommendation ID NG151/1 Question What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy

    Research recommendation
    Published
    10 February 2020

  4. Treatment for people with an IOP of 22 or 23 mmHg:- What is the clinical and cost effectiveness of treating an intraocular pressure (IOP) of 22 or 23 mmHg in people with normal optic discs and visual fields?

    Recommendation ID NG81/6 Question Treatment for people with an IOP of 22 or 23 mmHg:- What is the clinical and cost effectiveness of treating

    Research recommendation
    Published
    1 February 2022

  5. For people with active, drug susceptible TB who experience treatment interruptions because of adverse events, particularly hepatotoxicity, what approach to re-establishing treatment is mosteffective in reducing mortality and morbidity?

    Recommendation ID NG33/5 Question For people with active, drug susceptible TB who experience treatment interruptions because of adverse

    Research recommendation
    Published
    8 November 2019

  6. Standard principles of infection prevention and control:- What are the barriers to compliance with the standard principles of infection prevention and control that patients and carers experience in their own homes?

    Recommendation ID CG139/1 Question Standard principles of infection prevention and control:- What are the barriers to compliance with the

    Research recommendation
    Published
    9 June 2015

  7. Which patients, other than those known to have a high risk of complications or mortality, would benefit from postoperative care in a specialist recovery area (a high-dependency unit, a post-anaesthesia care unit or an intensive care unit)?

    Recommendation ID NG180/5 Question Which patients, other than those known to have a high risk of complications or mortality, would benefit

    Research recommendation
    Published
    26 October 2020

  8. Starting asthma treatment:- In adults, young people and children with asthma who have not been treated previously, is it more clinically and cost effective to start treatment with a reliever alone (a short-acting beta2 agonist [SABA]) or with a reliever (a SABA) and maintenance therapy (such as ICS)? Are there specificprognostic features that indicate that one of these treatment options may be more appropriate for some groups?

    Recommendation ID NG80/6 Question Starting asthma treatment:- In adults, young people and children with asthma who have not been treated

    Research recommendation
    Published
    18 October 2018

  9. Specific versus generic CBT for children and young people with social anxiety disorder:- What is the clinical and cost effectiveness of specific CBT for children and young people with social anxiety disorder compared with generic anxiety-focused CBT?

    Recommendation ID CG159/2 Question Specific versus generic CBT for children and young people with social anxiety disorder:- What is the

    Research recommendation
    Published
    9 June 2015

  10. What is the effectivness of statin treatment in older people?

    Recommendation ID NG238//2 Question What is the effectivness of statin treatment in older people? Any explanatory notes(if applicable)

    Research recommendation
    Published
    3 May 2024

  11. What staff training interventions are effective at facilitating personal recovery for people with complex psychosis?

    Recommendation ID NG181/7 Question What staff training interventions are effective at facilitating personal recovery for people with complex

    Research recommendation
    Published
    26 October 2020

  12. Stereotactic ablative radiotherapy compared with surgery: What is the effectiveness and cost effectiveness of stereotactic ablative radiotherapy (SABR) compared with surgery (for example, sublobar, wedge resection, lobectomy) for people with non-small-cell lung cancer (stage I and IIA) in whom surgery is suitable?

    Recommendation ID NG122/2 Question Stereotactic ablative radiotherapy compared with surgery: What is the effectiveness and cost effectiveness

    Research recommendation
    Published
    27 April 2023

  13. Stopping antiviral treatment in HBeAg-negative disease:- Further research should be undertaken to evaluate the clinical and cost effectiveness of hepatitis B surface antigen (HBsAg) quantitative assays in determining treatment duration in hepatitis B e antigen- (HBeAg) negative disease.

    Recommendation ID CG165/1 Question Stopping antiviral treatment in HBeAg-negative disease:- Further research should be undertaken to evaluate

    Research recommendation
    Published
    9 June 2015

  14. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    Recommendation ID NG56/3 Question Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines

    Research recommendation
    Published
    18 October 2016

  15. Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial growth factor (VEGF) treatment be suspended or stoppedin people with late AMD (wet)?

    Recommendation ID NG82/3 Question Stopping rules for antiangiogenic treatment for late AMD (wet):- When should anti-vascular endothelial

    Research recommendation
    Published
    13 November 2018